These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 23808005)

  • 21. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population.
    Agréus L; Storskrubb T; Aro P; Ronkainen J; Talley NJ; Sipponen P
    Scand J Gastroenterol; 2009; 44(5):564-70. PubMed ID: 19263272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic and serum risk markers for noncardia early gastric cancer.
    Shiotani A; Iishi H; Uedo N; Kumamoto M; Nakae Y; Ishiguro S; Tatsuta M; Graham DY
    Int J Cancer; 2005 Jun; 115(3):463-9. PubMed ID: 15688378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical parameters including serum pepsinogen level and management strategy in patients with premalignant gastric dysplasia.
    Chang YW; Hwangbo Y; Lee JW; Jo SJ; Cho JH; Shim J; Jang JY; Kim HJ; Kim BH
    Eur J Gastroenterol Hepatol; 2011 May; 23(5):405-10. PubMed ID: 21467942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Helicobacter pylori infection, but not mucosal atrophy, significantly affects serum pepsinogen level after gastric cancer surgery.
    Onoda N; Katsuragi K; Maeda K; Sawada T; Wakasa K; Hirakawa K
    Hepatogastroenterology; 2006; 53(70):619-23. PubMed ID: 16995475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastritis staging as a clinical priority.
    Mescoli C; Gallo Lopez A; Taxa Rojas L; Jove Oblitas W; Fassan M; Rugge M
    Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):125-129. PubMed ID: 29215433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
    Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
    Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicobacter pylori infection in combination with the serum pepsinogen I/II ratio and interleukin-1beta-511 polymorphisms are independent risk factors for gastric cancer in Thais.
    Yamada S; Matsuhisa T; Makonkawkeyoon L; Chaidatch S; Kato S; Matsukura N
    J Gastroenterol; 2006 Dec; 41(12):1169-77. PubMed ID: 17287896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pepsinogen I, pepsinogen II, and pepsinogen I/II ratio].
    Miki K; Sasajima M; Ohtsuka T; Urita Y
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():741-3. PubMed ID: 16149628
    [No Abstract]   [Full Text] [Related]  

  • 29. The new modified ABCD method for gastric neoplasm screening.
    Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
    Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
    Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma.
    Begum A; Baten MA; Begum Z; Ahsan MM; Rahman SF; Chowdhury F; Khan AH
    Mymensingh Med J; 2017 Jul; 26(3):628-634. PubMed ID: 28919620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
    Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
    Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study.
    Shikata K; Ninomiya T; Yonemoto K; Ikeda F; Hata J; Doi Y; Fukuhara M; Matsumoto T; Iida M; Kitazono T; Kiyohara Y
    Scand J Gastroenterol; 2012 Jun; 47(6):669-75. PubMed ID: 22428879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of serum pepsinogens and gross appearances combined with histology in early gastric cancer.
    Fujishiro M; Oka M; Yahagi N; Nakamura M; Kakushima N; Kodashima S; Kobayashi K; Hashimoto T; Yamamichi N; Moriyama Y; Tateishi A; Ono S; Shimizu Y; Ichinose M; Miki K; Omata M
    J Exp Clin Cancer Res; 2006 Jun; 25(2):207-12. PubMed ID: 16918132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea.
    Cho JH; Jeon SR; Kim HG; Jin SY; Park S
    Medicine (Baltimore); 2017 Jul; 96(29):e7603. PubMed ID: 28723806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric cancer screening using the serum pepsinogen test method.
    Miki K
    Gastric Cancer; 2006; 9(4):245-53. PubMed ID: 17235625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.
    Lee SA; Choi SR; Jang JS; Lee JH; Roh MH; Kim SO; Kim MC; Kim SJ; Jeong JS
    Dig Dis Sci; 2010 Jul; 55(7):1955-63. PubMed ID: 19757047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis.
    Kim EH; Kang H; Park CH; Choi HS; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
    Dig Liver Dis; 2015 Aug; 47(8):663-8. PubMed ID: 26077884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
    Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
    Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
    Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
    Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.